Explore more
Eli Lilly, Novo Nordisk and Zepbound
Digest more
Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, predicted that though Trump had spared the industry with tariffs, that wouldn't last much longer.
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
Gov. Mike Braun visited Lebanon Tuesday to help break ground for the $4.5 billion Eli Lilly Medicine Foundry in Lebanon. The foundry is the first research and development site of its kind in the world and will combine research,
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult diseases.
The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the workforce-talent pipeline.
Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to-earnings-to-growth (PEG) ratio of 0.4. PEGs below 1 are generally considered undervalued, so on that basis, the stock is very inexpensive.
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes drugs from compounding pharmacies.
The new research and development site will combine research, process development and clinical trial manufacturing capabilities into one plant.
Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, co-founder Patrick Hsu, Ph.D., told Fierce Biotech. | Stylus Medicine is unsheathing,
Feedback